



HAL
open science

Influence of the flavonoids apigenin; kaempferol and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1

Kathrin Mandery, Krystyna Bujok, Ingrid Schmidt, Markus Keiser, Werner Siegmund, Balk Bettina, König Jörg, Martin F. Fromm, Hartmut Glaeser

► **To cite this version:**

Kathrin Mandery, Krystyna Bujok, Ingrid Schmidt, Markus Keiser, Werner Siegmund, et al.. Influence of the flavonoids apigenin; kaempferol and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. *Biochemical Pharmacology*, 2010, 80 (11), pp.1746. 10.1016/j.bcp.2010.08.008 . hal-00632286

HAL Id: hal-00632286

<https://hal.science/hal-00632286v1>

Submitted on 14 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Influence of the flavonoids apigenin; kaempferol and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1

Authors: Kathrin Mandery, Krystyna Bujok, Ingrid Schmidt, Markus Keiser, Werner Siegmund, Bettina Balk, Jörg König, Martin F. Fromm, Hartmut Glaeser



PII: S0006-2952(10)00617-9
DOI: doi:10.1016/j.bcp.2010.08.008
Reference: BCP 10687

To appear in: *BCP*

Received date: 25-5-2010
Revised date: 9-8-2010
Accepted date: 10-8-2010

Please cite this article as: Mandery K, Bujok K, Schmidt I, Keiser M, Siegmund W, Jörg B, ,Fromm K, , MF, Glaeser H, Influence of the flavonoids apigenin; kaempferol and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1, *Biochemical Pharmacology* (2010), doi:10.1016/j.bcp.2010.08.008

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3
4 **Influence of the flavonoids apigenin, kaempferol and**
5
6
7 **quercetin on the function of organic anion transporting**
8
9
10 **polypeptides 1A2 and 2B1**
11
12
13
14
15
16
17
18

19 Kathrin Mandery^{a#}, Krystyna Bujok^{a#}, Ingrid Schmidt^a, Markus Keiser^b, Werner Siegmund^b,
20 Bettina Balk^a, Jörg König^a, Martin F. Fromm^a, Hartmut Glaeser^a
21
22
23
24
25

26 ^aInstitute of Experimental and Clinical Pharmacology and Toxicology, Friedrich-Alexander-
27 University Erlangen-Nuremberg, Fahrstraße 17, 91954 Erlangen, Germany
28
29

30 Kathrin.mandery@pharmakologie.med.uni-erlangen.de
31

32 Krystyna.bujok@t-online.de
33

34 schmidt@pharmakologie.med.uni-erlangen.de
35

36 bettina.balk@gmx.de
37

38 Joerg.koenig@pharmakologie.med.uni-erlangen.de
39

40 fromm@pharmakologie.med.uni-erlangen.de
41

42 glaeser@pharmakologie.med.uni-erlangen.de
43
44
45
46
47

48 ^bDepartment of Pharmacology, Research Center of Pharmacology and Experimental
49 Therapeutics, Ernst-Moritz-Arndt-University, Friedrich-Loeffler-Str. 23d, 17487 Greifswald,
50
51
52
53 Germany

54 mkeiser@uni-greifswald.de
55

56 siegmuw@uni-greifswald.de
57
58

59 # both authors contributed equally to the study
60
61
62
63
64
65

1
2
3
4 **Corresponding author**

5
6 Hartmut Glaeser, PhD

7
8 Friedrich-Alexander-University Erlangen-Nuremberg

9
10 Institute of Experimental and Clinical Pharmacology and Toxicology

11
12 Fahrstr. 17

13
14 91054 Erlangen

15
16 Germany

17
18 Tel: +49-9131-85-21128

19
20 Fax: +49-9131-85-22773

21
22 E-mail: hartmut.glaeser@pharmakologie.med.uni-erlangen.de

23
24
25
26
27
28 **Abbreviations**

29
30 OATP organic anion transporting polypeptide

31
32 BSP sulphobromophthalein

33
34 HEK human embryonic kidney

35
36 IC₅₀ concentration with 50% inhibition

37
38 K_i inhibitory constant

39
40 SLCO solute carrier organic anion transporter

41
42 VC vector control

1 Abstract

OATP1A2 and OATP2B1 are uptake transporters of the human organic anion transporting polypeptide (OATP) family with a broad substrate spectrum including several endogenous compounds as well as drugs such as the antihistaminic drug fexofenadine and HMG-CoA reductase inhibitors. Both transporters are localized in the apical membrane of human enterocytes. Flavonoids, abundantly occurring in plants, have previously been shown to interact with drug metabolizing enzymes and transporters. However, the impact of flavonoids on OATP1A2 and OATP2B1 transport function has not been analyzed in detail. Therefore, HEK293 cell lines stably expressing OATP1A2 and OATP2B1 were used to investigate the influence of the Ginkgo flavonoids apigenin, kaempferol, and quercetin on the transport activity of OATP1A2 and OATP2B1. K_i values of all three flavonoids determined from Dixon plot analyses using BSP as substrate indicated a competitive inhibition with quercetin as the most potent inhibitor of OATP1A2 (22.0 μ M) and OATP2B1 (8.7 μ M) followed by kaempferol (OATP1A2: 25.2 μ M, OATP2B1: 15.1 μ M) and apigenin (OATP1A2: 32.4 μ M OATP2B1: 20.8 μ M). Apigenin, kaempferol, and quercetin led to a concentration-dependent decrease of the OATP1A2-mediated fexofenadine transport with IC_{50} values of 4.3 μ M, 12.0 μ M, and 12.6 μ M, respectively. The OATP1A2- and OATP2B1-mediated transport of atorvastatin was also efficiently inhibited by apigenin (IC_{50} for OATP1A2: 9.3 μ M, OATP2B1: 13.9 μ M), kaempferol (IC_{50} for OATP1A2: 37.3 μ M, OATP2B1: 20.7 μ M) and quercetin (IC_{50} for OATP1A2: 13.5 μ M, OATP2B1: 14.1 μ M). These data indicate that

1
2
3
4 modification of OATP1A2 and OATP2B1 transport activity by apigenin, kaempferol, and
5
6 quercetin may be a mechanism for food-drug or drug-drug interactions in humans.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Accepted Manuscript

2 Keywords

organic anion transporting polypeptide

flavonoids

drug-drug interaction

fexofenadine

inhibition

herbal drugs

Accepted Manuscript

3 Introduction

Flavonoids represent the most abundant polyphenols in vegetables, fruits, and plants. They are also ingredients of tea, wine, juices, numerous multivitamin preparations and herbal products (e.g. Ginkgo biloba formulations). In vitro and in vivo studies indicate pharmacological effects of flavonoids on prevention of cardiovascular diseases as well as anticancerogenic and antioxidative effects [1-4].

It has recently been shown that several of these compounds inhibit drug metabolizing enzymes and drug transporters such as cytochrome P450 3A4 and the drug efflux transporter P-glycoprotein (ABCB1) [5], highlighting their potential for food-drug interactions. For example, the flavonoids apigenin, kaempferol, and quercetin which are constituents of Ginkgo biloba formulations, onions, strawberries, and apples [2] were characterized by inhibition and/or induction of CYP3A4, ABCB1, and ABCC2 [6-7]. OATP1A2 and OATP2B1 are members of the human OATP family and are localized in the apical membrane of human enterocytes [8-9]. OATP1A2 mediates the intracellular uptake of drugs such as fexofenadine [10] as well as of endogenous compounds such as taurocholate [11]. OATP2B1 mediates the cellular uptake of drugs such as fluvastatin [12], atorvastatin [13] and of endogenous compounds such as estrone-3-sulfate [14].

The influence of flavonoids on intestinal drug metabolism and transport is of special interest because flavonoids such as apigenin, kaempferol, and quercetin can reach high concentrations in the gut lumen. The inhibition of an OATP-mediated drug uptake in the intestine may decrease the plasma concentration of a substrate of OATPs, due to a reduced absorption.

1
2
3
4 In vitro studies in HeLa cells and additional in vivo studies showed that the flavonoid
5
6 naringin, a constituent of grapefruit juice, inhibits the uptake of fexofenadine mediated
7
8 by OATP1A2 [9, 15-16]. This inhibition leads to a reduced area under the plasma
9
10 concentration time curve (AUC) of the OATP1A2 substrate fexofenadine when
11
12 grapefruit juice is coadministered with orally taken fexofenadine. Grapefruit juice or
13
14 orange juice at a concentration of 5% significantly inhibited the OATP2B1-mediated
15
16 uptake of estrone-3-sulfate by 82% and 53% in HEK293 cells stably expressing
17
18 OATP2B1 [17].
19
20
21

22
23 Furthermore it was shown in an in vitro study that several herbal extracts, such as
24
25 Ginkgo biloba extracts, potently inhibited the OATP2B1-mediated uptake of estrone-3-
26
27 sulfate in HEK293 cells. These results suggest that coadministration of some dietary
28
29 supplements may decrease the absorption of orally administered OATP2B1 substrates
30
31 [18].
32
33

34
35 However, there are no data showing the influence of the flavonoids apigenin,
36
37 kaempferol, and quercetin, which are chemically related to the grapefruit juice flavonoid
38
39 naringin, on the function of human intestinal OATPs such as OATP1A2 and OATP2B1.
40
41 Therefore, we investigated the potential influence of the flavonoids apigenin,
42
43 kaempferol, and quercetin on the transport function of OATP1A2 and OATP2B1 in order
44
45 to gain more insights regarding further possible mechanisms of food-drug or drug-drug
46
47 interactions. Changes in function of the OATP1A2- and OATP2B1-mediated drug
48
49 uptake by apigenin, kaempferol, and quercetin may influence the absorption and
50
51 systemic exposure of OATP substrates. Considering the frequent intake of herbal
52
53 preparations of Ginkgo biloba, vegetables, and fruits containing these flavonoids, the
54
55 hypothesized interaction with the intestinal uptake transporters OATP1A2 and
56
57
58
59
60
61
62
63
64
65

1
2
3
4 OATP2B1 might be an important determinant of intraindividual variability of drug
5
6 disposition.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 Methods

4.1 Chemicals

[³H]Sulphobromophthalein (14 Ci/mmol) was obtained from Hartmann Analytic (Braunschweig, Germany). Unlabeled sulphobromophthalein was purchased from Applichem GmbH (Darmstadt, Germany). Sodium butyrate was purchased from Merck KGaA (Darmstadt, Germany). Apigenin (purity ≥ 95.0%, HPLC), kaempferol (purity ≥ 96%, HPLC), quercetin (purity ≥ 98%, HPLC), and fexofenadine hydrochloride were purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany). [³H]Atorvastatin (10 Ci/mmol) and unlabeled atorvastatin were obtained from BioTrend Chemikalien GmbH (Cologne, Germany) and Toronto Research Chemicals Inc. (North York, ON, Canada), respectively. All compounds were dissolved in dimethyl sulfoxide (Carl Roth GmbH + Co. KG, Karlsruhe, Germany). All other chemicals and reagents, unless stated otherwise, were obtained from Carl Roth GmbH + Co. KG (Karlsruhe, Germany) and were of the highest grade available.

4.2 Generation of a HEK293 cell line stably expressing OATP1A2

The *SLCO1A2* coding sequence (NM_134431.3) was cloned by reverse transcription reaction and subsequent polymerase chain reaction from human brain cDNA (Human Total RNA Master Panel II, Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) into the pcDNA3.1(+) vector (Invitrogen GmbH, Karlsruhe, Germany) and

1
2
3
4 subcloned into the retroviral vector pQCXIN (Takara Bio Europe/Clontech, Saint-
5
6 Germain-en-Laye, France). Human embryonic kidney cells (HEK293) were transfected
7
8 with the plasmid pQCXIN-OATP1A2 using a retroviral gene transfer and expression kit
9
10 (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France). After geneticin (G-418;
11
12 500 µg/ml) treatment, single colonies were selected and characterized for OATP1A2
13
14 mRNA and protein expression using real-time PCR, immunofluorescence, and
15
16 immunoblot analysis as previously described [19-20]. The polyclonal rabbit anti human
17
18 OATP1A2 antiserum was kindly provided by Professor Richard B. Kim (Division of
19
20 Clinical Pharmacology, Department of Medicine, Schulich School of Medicine &
21
22 Dentistry, The University of Western Ontario, London, Ontario, Canada). The primer for
23
24 real-time PCR analysis of *SLCO1A2* mRNA were forward: 5'-
25
26 AAGACCAACGCAGGATCCAT -3' and reverse: 5'-GAGTTTCACCCATTCCACGTACA
27
28 -3' with a resulting amplicon size of 101 base pairs. The primers for the housekeeping
29
30 gene β -actin were forward: 5'-TGACGGGGTCACCCACACTGTGCCCATCTA-3' and
31
32 reverse: 5'-CTAGAAGCATTGCGGTGGACGATGGAGGG-3' with a resulting amplicon
33
34 size of 661 base pairs. The secondary antibodies for immunofluorescence and
35
36 immunoblot analyses were used as previously published [19]. HEK293-VC (VC: vector
37
38 control) cells were established by the same method using the plasmid lacking the insert
39
40 for transfection.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **4.3 Cell culture**

55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 HEK293-OATP1A2 cells were cultured in minimum essential medium containing 10 %
5
6 heat-inactivated fetal bovine serum, 2mM non essential amino acids, 500 µg/ml
7
8 geneticin, 100 U/ml penicillin, and 100 µg/ml streptomycin at 37 °C and 5 % CO₂.

9
10
11 HEK293-OATP2B1 cells [21-22] were cultured in minimum essential medium containing
12
13 10 % heat-inactivated fetal bovine serum, 800 µg/ml geneticin, 100 U/ml penicillin, and
14
15 100 µg/ml streptomycin at 37 °C and 5 % CO₂. The cells were routinely subcultured by
16
17 trypsinization using trypsin (0.05 %)-EDTA (0.02 %) solution. All cell culture media
18
19 supplements were obtained from Invitrogen GmbH (Karlsruhe, Germany).
20
21
22
23
24
25
26

27 **4.4 Transport assays**

28
29
30
31
32 The uptake experiments were performed as previously described [19-20]. Briefly,
33
34 HEK293-OATP1A2, HEK293-OATP2B1, and the respective HEK293-VC cells were
35
36 seeded in poly-D-lysine coated 12-well plates at an initial density of 7.5×10^5 cells / well.
37
38 After 24 h, cells were treated with sodium butyrate for 24 h prior to the uptake
39
40 experiments in order to increase the levels of the recombinant protein [23]. First, cells
41
42 were incubated with prewarmed (37 °C) uptake buffer (142 mM NaCl, 5 mM KCl, 1 mM
43
44 K₂HPO₄, 1.2 mM MgSO₄, 1.5 mM CaCl₂, 5 mM glucose, and 12.5 mM HEPES, pH 7.3)
45
46 containing a mix of radiolabeled (0.01 µM) and nonradiolabeled BSP or atorvastatin.
47
48
49
50
51 HEK293-OATP1A2 cells were incubated with BSP (concentrations see below) and
52
53 atorvastatin (5 µM) for five minutes and 10 minutes, respectively. OATP2B1 cells were
54
55 incubated with BSP and atorvastatin for 10 minutes. HEK293-OATP1A2 and HEK293-
56
57 VC cells were incubated with unlabeled fexofenadine (5 µM) for 5 minutes. Estimation of
58
59
60
61
62
63
64
65

1
2
3
4 the inhibitory constants (K_i) of flavonoids for OATP1A2 and OATP2B1 were performed
5
6 using Dixon-Plot analyses [24]. The OATP1A2-mediated BSP net uptake was
7
8 determined at concentrations of 2.5, 5.0 and 10 μM after an incubation of 5 minutes in
9
10 absence or presence of increasing concentrations of flavonoids (apigenin: 1, 10,
11
12 100 μM ; kaempferol: 10, 50, 100 μM for OATP1A2; 1, 10, 100 μM for OATP2B1;
13
14 quercetin: 25, 50, 100 μM). For OATP2B1, the BSP net uptake was determined using
15
16 concentrations of 0.5, 1.0 and 2.5 μM at 10 minutes of incubation in absence or
17
18 presence of increasing concentrations of flavonoids (see above). After incubation cells
19
20 were lysed with 0.2% sodium dodecyl sulfate and the intracellular accumulation of
21
22 radioactivity was determined in 500 μl of cells lysates by liquid scintillation counting
23
24 (TriCarb 2800, PerkinElmer Life Sciences GmbH). The appropriate protein
25
26 concentration of each well was determined in 25 μl of cells lysates by bichinchoninic
27
28 acid assay (BCA Protein Assay Kit; Thermo Scientific). The net uptake was expressed
29
30 as $\text{pmol} \cdot \text{mg protein}^{-1} \cdot \text{min}^{-1}$. Furthermore, a concentration dependent inhibition of
31
32 OATP1A2-mediated fexofenadine transport was investigated at concentration of
33
34 flavonoids ranging from 1 μM to 750 μM . The influence on the OATP1A2- and
35
36 OATP2B1-mediated uptake of atorvastatin was investigated at a concentration range
37
38 between 0,1 μM and 250 μM of flavonoids. Measurements were repeated for each
39
40 concentration three to six times.
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **4.5 Quantitation of fexofenadine by LC-MS/MS**

55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 The quantitation of fexofenadine by LC-MS/MS was performed as previously described
5
6 [25]. In brief, 10 μ l of samples were prepared by addition of 90 μ l of internal standard
7
8 solution (MDL 026042, kindly provided by Aventis Pharma Deutschland GmbH,
9
10 Frankfurt a.M., Germany) to 100 μ l of the cell lysates. Analysis was performed using the
11
12 triple quadrupole system API 4000™ LC-MS/MS System (Applied Biosystems, Toronto,
13
14 ON, Canada). The HPLC column used was a Luna 3u CN 100A, New Column 100 x 2.0
15
16 mm with SecurityGuard Cartridges, CN 4 x 2.0 mm purchased from Phenomenex
17
18 (Aschaffenburg, Germany). A mixture of 12 mM ammonium acetate and acetonitril
19
20 (50:50, v/v) was used as mobile phase. The flow rate was set at 0.25 ml/min. The lower
21
22 limit of quantitation was 0.5 ng/ml. The peak area ratio of fexofenadine to the internal
23
24 standard was calculated using Analyst software v1.4.2 (Applied Biosystems, Darmstadt,
25
26 Germany). The retention time of fexofenadine and of the internal standard was 2.0 min.
27
28 The calibration curves were linear over the range from 0.5 to 100 ng/ml with a mean
29
30 correlation coefficient of 0.9992. The mass spectrometer was operated in the selected
31
32 ion monitoring mode using the respective MH^+ ions, m/z 502.3 for fexofenadine and m/z
33
34 530.3 for the internal standard. Coefficient of variation (CV) of the interassay variability
35
36 (n = 15; quality controls containing 2.5, 25 and 100 ng/ml of fexofenadine) ranged
37
38 between 4.0 and 6.6 %. The CV of the intraassay variability (n = 5) ranged between 3.4
39
40 and 7.4 %. The appropriate protein concentration of each well was determined in 25 μ l
41
42 of cells lysates by bichinchoninic acid assay (BCA Protein Assay Kit; Thermo Scientific).
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **4.6 Data and statistical Analysis**

57
58
59
60
61
62
63
64
65

1
2
3
4 The OATP1A2- and OATP2B1- mediated net uptake was obtained by subtracting the
5
6 uptake in VC cells from that in OATP1A2- and OATP2B1-expressing cells. The
7
8 percentage of uptake inhibition was calculated from control experiments in the absence
9
10 of flavonoids (100% uptake). The corresponding IC_{50} values for inhibition of OATP1A2-
11
12 mediated fexofenadine uptake were calculated by fitting the data to a sigmoid dose-
13
14 response regression curve (GraphPad Prism 5.00 for Windows; GraphPad Software,
15
16 San Diego, CA, USA). The IC_{50} value is the concentration at which 50% inhibition of
17
18 substrate uptake is obtained. To determine the type of inhibitory interaction of flavonoids
19
20 with the OATP1A2- and OATP2B1-mediated BSP uptake, the uptake of $^3[H]BSP$ was
21
22 determined in the presence of increasing concentrations of flavonoids. K_i values were
23
24 calculated by the method of Dixon, in which the reciprocal velocity, $1/V$, is plotted
25
26 against the concentration of the inhibitor. The OATP1A2-mediated uptake of BSP and
27
28 atorvastatin was analyzed using an unpaired t-test with Welch's correction. The
29
30 calculations were performed using GraphPad Prism 5.00. All data are presented as
31
32 means \pm S.E.M. A value of $p \leq 0.05$ was considered statistically significant.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

5 Results

5.1 *Characterization of a HEK293 cell line stably expressing OATP1A2*

In the present study, we established a HEK293 cell line stably expressing the human uptake transporter OATP1A2. The selected cell clones of the HEK293-OATP1A2 and HEK293-VC cells were investigated regarding their expression, localization, and function of OATP1A2 using real-time PCR, immunoblot and immunofluorescence analysis. The HEK293-OATP1A2 cells were characterized by a significantly higher expression of *SLCO1A2* mRNA and OATP1A2 protein compared to the control cells (figure 1a, b). The immunofluorescence analysis revealed that OATP1A2 is localized in the plasma membrane and to a lower extent in the cytosol of HEK293-OATP1A2 cells. No staining was observed in HEK293-VC cells (figure 1c). The functional characterization showed a 2.4-fold ($p < 0.0001$, $df = 25$) and 6.9-fold ($p < 0.0001$, $df = 5$) higher uptake of BSP (5 μM) and atorvastatin (5 μM), respectively, into the HEK293-OATP1A2 cells compared to HEK293-VC cells (figure 1d, e) demonstrating that both compounds are substrates of OATP1A2.

5.2 *Influence of flavonoids on the OATP1A2- and OATP2B1-mediated uptake of BSP*

1
2
3
4 In order to investigate the inhibitory effects of apigenin, kaempferol, and quercetin on
5
6 the transport function of OATP1A2 and OATP2B1, the K_i values of these flavonoids for
7
8 inhibition of OATP1A2- and OATP2B1-mediated BSP uptake (measured by liquid
9
10 scintillation counting) were determined. To evaluate the type of interaction of flavonoids
11
12 with OATP1A2- and OATP2B1-mediated transport of BSP, Dixon plot analyses were
13
14 performed (figure 2). The lines drawn for each concentration of substrate intersect at a
15
16 single point above the x-axis indicating that all flavonoids influence both OATP
17
18 transporters by competitive inhibition. The K_i values of all three flavonoids determined
19
20 from the Dixon plots were lower for OATP2B1 compared to OATP1A2 (figure 2).
21
22 Quercetin was the most potent inhibitor of the OATP1A2-mediated BSP uptake followed
23
24 by kaempferol and apigenin ($22.0 \pm 5.9 \mu\text{M}$, $25.2 \pm 13.0 \mu\text{M}$, and $32.4 \pm 12.2 \mu\text{M}$). For
25
26 OATP2B1 quercetin was also the most potent inhibitor followed by kaempferol and
27
28 apigenin ($8.7 \pm 0.1 \mu\text{M}$, $15.1 \pm 7.8 \mu\text{M}$, and $20.8 \pm 8.0 \mu\text{M}$).
29
30
31
32
33
34
35
36
37
38

39 ***5.3 Influence of flavonoids on the OATP1A2- and OATP2B1-mediated*** 40 41 ***uptake of drugs*** 42 43 44 45 46

47 To determine whether apigenin, kaempferol, and quercetin alter the OATP1A2-
48
49 mediated transport of fexofenadine (measured by LC-MS/MS), inhibition studies were
50
51 performed (figure 3). Because we previously found that fexofenadine is not a substrate
52
53 of OATP2B1 [9] only the impact of flavonoids on the OATP1A2-mediated uptake of
54
55 fexofenadine was investigated. Apigenin was the most potent inhibitor of OATP1A2-
56
57 mediated fexofenadine transport with the lowest IC_{50} value followed by kaempferol and
58
59
60
61
62
63
64
65

1
2
3
4 quercetin ($4.3 \pm 1.5 \mu\text{M}$, $12.0 \pm 1.2 \mu\text{M}$, and $12.6 \pm 1.3 \mu\text{M}$). Secondly, the influence of
5
6 apigenin, kaempferol and quercetin on the OATP1A2- and OATP2B1-mediated
7
8 atorvastatin transport (measured by liquid scintillation counting) was investigated (figure
9
10 4). Apigenin and quercetin were the most effective inhibitors for the OATP1A2- and
11
12 OATP2B1-mediated atorvastatin uptake. For OATP1A2 the IC_{50} values of apigenin and
13
14 quercetin were 9.3 ± 1.5 and $13.5 \pm 1.7 \mu\text{M}$. The IC_{50} values of apigenin and quercetin
15
16 for OATP2B1 were with $13.9 \pm 1.6 \mu\text{M}$ and $14.1 \pm 1.3 \mu\text{M}$ very similar. Kaempferol
17
18 showed the lowest inhibitory potency of the OATP1A2- and OATP2B1-mediated
19
20 atorvastatin transport compared to apigenin and quercetin (IC_{50} for OATP1A2:
21
22 $37.3 \pm 1.6 \mu\text{M}$, IC_{50} for OATP2B1: $20.7 \pm 1.8 \mu\text{M}$).

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

6 Discussion

The major findings of the present study were that the flavonoids apigenin, kaempferol and quercetin affect the transport function of OATP1A2- and OATP2B1-mediated uptake of BSP and of the drugs fexofenadine and atorvastatin.

Because most of the drugs used in pharmacotherapy are orally administered, the bioavailability of these compounds can already be influenced by intestinal drug transport and metabolism. Drug uptake transporters such as OATP1A2 expressed in the apical membrane of enterocytes [9] seem to influence the intestinal absorption of drugs such as fexofenadine [9-10, 16]. The absorption of fexofenadine, which is not metabolized in humans, is reduced when fexofenadine is coadministered with grapefruit juice due to an inhibition of OATP1A2-mediated fexofenadine uptake by the flavonoid naringin [15].

Vegetables, fruits, and herbal drugs are rich of flavonoids and therefore, we investigated the influence of the flavonoids apigenin, kaempferol, and quercetin on the transport activity of intestinal transporters OATP1A2 and OATP2B1 which are expressed in the apical membrane of enterocytes [8-9].

The amount of apigenin, kaempferol, and quercetin is different within vegetables and herbal drugs. Interestingly, a study indicated that quercetin is more abundant compared to kaempferol in vegetables and fruits such as onions, lettuce, french bean, and apples [26]. High amounts of quercetin were detected in onions and apples with mean values of 347 and 36 mg / kg of fresh edible part, respectively [26]. Kaempferol showed the highest amounts in leek and endive with values of 30 and 46 mg / kg of fresh edible part, respectively. A further analyses of different beverages revealed that quercetin can

1
2
3
4 be found in red wine (highest concentration measured: 16 mg/l), apple juice, tomato
5
6 juice, and different tea brands [2]. Taken the high and regular consumption of these
7
8 vegetables, fruits, and beverages into consideration, it seems comprehensible that the
9
10 concomitant intake of such foods with drugs such as fexofenadine or atorvastatin may
11
12 lead to a reduced absorption of these drugs. Therefore, the inhibition of intestinal
13
14 OATPs by flavonoids could lead, in addition to the modification of cytochrome P450
15
16 enzymes and ABC-transporters, to an altered pharmacokinetic and pharmacodynamic
17
18 of drugs.
19
20
21
22

23
24 The flavonoids apigenin, kaempferol, and quercetin and their glycosides are also the
25
26 major constituents of herbal drug preparations of Ginkgo biloba. A study investigating
27
28 different extracts of commercially available Ginkgo biloba preparations showed that in
29
30 the analyzed extracts approximately 30 % of the active substances were flavone
31
32 glycosides [27]. Most of these glycosides will be deglycosylated by a β -glucosidase
33
34 (lactase-phlorizin hydrolase) localized in the apical membrane of enterocytes [28]. This
35
36 enzyme may increase the access of the deglycosylated apigenin, kaempferol, and
37
38 quercetin to OATP1A2 and OATP2B1.
39
40
41
42

43
44 A pure preparation of 500 mg quercetin (Quercetin-500 Plus[®]), available as dietary
45
46 supplement (<http://supplementspot.com>), taken with 300 ml of water could lead to a
47
48 maximal intestinal concentration of 5514 μ M. This shows that these supplements could
49
50 lead to concentrations of quercetin in the intestine high enough to influence the
51
52 transport activity of OATP1A2 and OATP2B1.
53
54

55
56 The presented data indicate that the flavonoids apigenin, kaempferol, and quercetin
57
58 inhibit the OATP1A2- and OATP2B1-mediated uptake of substrates into HEK293 cells
59
60 by a competitive mechanism. Therefore, these flavonoids could be also substrates of
61
62
63
64
65

1
2
3
4 OATP1A2 and OATP2B1. A study with Caco-2 cells provided some in vitro evidence
5
6 that OATP2B1 may be involved in the translocation of quercetin from the apical to the
7
8 basal compartment [29]. Quercetin seems to be a potent inhibitor of the OATP1A2- and
9
10 OATP2B1-mediated transport represented by the determined K_i values in this study.
11
12 Interestingly, quercetin is also a potent inhibitor of CYP3A4 and P-glycoprotein [30].
13
14 Considering that quercetin is also one of the most abundant flavonoids, foods and
15
16 herbal preparations containing quercetin may be therefore associated with a high risk
17
18 for food-drug or drug-drug interactions by influencing the intestinal drug uptake,
19
20 metabolism, and excretion. Furthermore, the potency of inhibition of OATP1A2 and
21
22 OATP2B1 by apigenin and quercetin was different for the investigated substrates BSP,
23
24 fexofenadine and atorvastatin. Quercetin was the most potent inhibitor of the OATP1A2-
25
26 and OATP2B1-mediated BSP transport, whereas apigenin was the strongest inhibitor of
27
28 the OATP1A2-mediated atorvastatin and fexofenadine transport. For the OATP2B1-
29
30 mediated atorvastatin transport no difference in the potency between apigenin and
31
32 quercetin was observed.
33
34
35
36
37
38
39
40
41
42

43 Some in vivo studies indicate an interaction between herbal drugs such as Ginkgo
44
45 biloba preparations and the transporter-mediated absorption of drugs. A study
46
47 investigated the influence of Ginkgo biloba extract on the pharmacokinetics of
48
49 fexofenadine [31]. After an intake of Ginkgo biloba extract (120 mg bid) for two weeks a
50
51 non significant reduction by 20 % in fexofenadine AUC was observed. However, it is not
52
53 stated whether fexofenadine (120 mg) and Ginkgo biloba extract (120 mg) were given
54
55 simultaneously. Therefore, it could be speculated that the lack of significance is caused
56
57
58
59
60 by a non simultaneous administration of Ginkgo biloba extract and fexofenadine.
61
62
63
64
65

1
2
3
4 Our data are in line with a previous publication showing that Ginkgo leaf extracts and
5
6 quercetin-3-glucoside, quercetin-3-rutinoside, kaempferol-3-glucoside, and kaempferol-
7
8 3-rutinoside inhibited the OATP2B1-mediated transport of estrone-3-sulfate in HEK293-
9
10 cells stably expressing OATP2B1 [18].
11

12
13
14 In the present study we also established HEK293 cells stably expressing OATP1A2. In
15
16 previous studies investigating the function of OATP1A2, *Xenopus laevis* oocytes or HeLa
17
18 cells transiently expressing OATP1A2 were used [10-11]. To the best of our knowledge,
19
20 this is the first study using HEK293 cells stably expressing OATP1A2. In addition, we
21
22 were able to show that atorvastatin is a substrate of OATP1A2 which was already
23
24 published previously [32]. Because atorvastatin is a frequently used drug, the inhibition
25
26 of OATP1A2-mediated atorvastatin transport by flavonoids should be considered as a
27
28 possible new mechanism for food-drug or drug-drug interactions. However, atorvastatin
29
30 is also a substrate of CYP3A4, P-glycoprotein, and OATP2B1. Considering all the
31
32 possible changes in the pharmacokinetics of atorvastatin due to the modulation of
33
34 CYP3A4, P-glycoprotein, OATP1A2 and OATP2B1 and also the pharmacogenomics of
35
36 P-glycoprotein, OATP1A2, and OATP2B1 it becomes obvious that in vivo studies are
37
38 necessary to clarify the clinical relevance of flavonoid-mediated drug interactions with
39
40 atorvastatin. An in vivo study investigating the interaction between grapefruit juice and
41
42 atorvastatin or pravastatin showed an increase in T_{max} of atorvastatin and pravastatin
43
44 [33]. Grapefruit juice was ingested for two days and on day 3 with the drugs, 0.5 h and
45
46 1.5 h after drug intake. It could be speculated that the inhibition of OATP1A2- and
47
48 OATP2B1-mediated uptake of atorvastatin (OATP1A2 and OATP2B1) and pravastatin
49
50 (OATP2B1) by grapefruit juice may be responsible for the observed effects.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 Taken together, our study shows that the inhibition of OATP1A2- and OATP2B1-
5
6 mediated transport by apigenin, kaempferol, and quercetin should be considered as a
7
8 potential, new mechanism for food-drug or drug-drug interactions. The clinical relevance
9
10 of the observed interactions needs to be elucidated in clinical interactions studies.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

7 Acknowledgements

This work was funded by a grant of the Deutsche Forschungsgemeinschaft [DFG GL 588/2-1] and the German Federal Ministry of Education and Research [grant, InnoProfile 03IP612].

Accepted Manuscript

8 References

- [1] Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet* 1993;342:1007-11.
- [2] Hertog MGL, Hollman PC, van de Putte B. Content of Potentially Anticarcinogenic Flavonoids of Tea Infusions, Wines, and Fruit Juices. *J Agric Food Chem* 1993;41:1242-46.
- [3] Jagtap S, Meganathan K, Wagh V, Winkler J, Hescheler J, Sachinidis A. Chemoprotective mechanism of the natural compounds, epigallocatechin-3-O-gallate, quercetin and curcumin against cancer and cardiovascular diseases. *Curr Med Chem* 2009;16:1451-62.
- [4] Boots AW, Haenen GR, Bast A. Health effects of quercetin: from antioxidant to nutraceutical. *Eur J Pharmacol* 2008;585:325-37.
- [5] Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-drug interactions. *J Neuroimmune Pharmacol* 2006;1:323-39.
- [6] Alvarez AI, Real R, Perez M, Mendoza G, Prieto JG, Merino G. Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response. *J Pharm Sci* 2010;99:598-617.
- [7] Pal D, Mitra AK. MDR- and CYP3A4-mediated drug-herbal interactions. *Life Sci* 2006;78:2131-45.
- [8] Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent

- 1
2
3
4 transport across intestinal apical membrane. J Pharmacol Exp Ther
5
6 2003;306:703-8.
7
8
- 9 [9] Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, et al.
10 Intestinal drug transporter expression and the impact of grapefruit juice in
11 humans. Clin Pharmacol Ther 2007;81:362-70.
12
13
- 14 [10] Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-
15 glycoprotein transporters mediate the cellular uptake and excretion of
16 fexofenadine. Drug Metab Dispos 1999;27:866-71.
17
18
- 19 [11] Kullak-Ublick GA, Hagenbuch B, Stieger B, Schteingart CD, Hofmann AF,
20 Wolkoff AW, et al. Molecular and functional characterization of an organic anion
21 transporting polypeptide cloned from human liver. Gastroenterology
22 1995;109:1274-82.
23
24
- 25 [12] Kopplow K, Letschert K, König J, Walter B, Keppler D. Human hepatobiliary
26 transport of organic anions analyzed by quadruple-transfected cells. Mol
27 Pharmacol 2005;68:1031-8.
28
29
- 30 [13] Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, et al. Organic anion
31 transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is
32 expressed in the human heart. Clin Pharmacol Ther 2006;80:607-20.
33
34
- 35 [14] Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular
36 identification and characterization of novel members of the human organic anion
37 transporter (OATP) family. Biochem Biophys Res Commun 2000;273:251-60.
38
39
- 40 [15] Bailey DG, Dresser GK, Leake BF, Kim RB. Naringin is a major and selective
41 clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in
42 grapefruit juice. Clin Pharmacol Ther 2007;81:495-502.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [16] Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al.
5
6 Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake
7
8 to decrease the oral availability of fexofenadine. Clin Pharmacol Ther
9
10 2002;71:11-20.
11
12
13 [17] Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, et al.
14
15 Citrus juices inhibit the function of human organic anion-transporting polypeptide
16
17 OATP-B. Drug Metab Dispos 2005;33:518-23.
18
19
20 [18] Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of
21
22 herbal extracts on the function of human organic anion-transporting polypeptide
23
24 OATP-B. Drug Metab Dispos 2006;34:577-82.
25
26
27 [19] Glaeser H, Mandery K, Sticht H, Fromm MF, König J. Relevance of conserved
28
29 lysine and arginine residues in transmembrane helices for the transport activity of
30
31 organic anion transporting polypeptide 1B3. Br J Pharmacol 2010;159:698-708.
32
33
34 [20] Mandery K, Bujok K, Schmidt I, Wex T, Treiber G, Malfertheiner P, et al.
35
36 Influence of cyclooxygenase inhibitors on the function of the prostaglandin
37
38 transporter organic anion-transporting polypeptide 2A1 expressed in human
39
40 gastroduodenal mucosa. J Pharmacol Exp Ther 2010;332:345-51.
41
42
43 [21] Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic
44
45 drugs with hepatic uptake transporters: focus on organic anion transporting
46
47 polypeptides and organic cation transporter 1. Diabetes 2008;57:1463-9.
48
49
50 [22] Kraft M, Glaeser H, Mandery K, König J, Auge D, Fromm MF, et al. The
51
52 prostaglandin transporter OATP2A1 is expressed in human ocular tissues and
53
54 transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 [23] Cui Y, König J, Buchholz JK, Spring H, Leier I, Keppler D. Drug resistance and
5
6 ATP-dependent conjugate transport mediated by the apical multidrug resistance
7
8 protein, MRP2, permanently expressed in human and canine cells. *Mol*
9
10 *Pharmacol* 1999;55:929-37.
11
12
13
14 [24] Dixon M. The graphical determination of K_m and K_i . *Biochem J* 1972;129:197-
15
16 202.
17
18
19 [25] Hofmann U, Seiler M, Drescher S, Fromm MF. Determination of fexofenadine in
20
21 human plasma and urine by liquid chromatography-mass spectrometry. *J*
22
23 *Chromatogr B Analyt Technol Biomed Life Sci* 2002;766:227-33.
24
25
26 [26] Hertog MGL, Hollman PC, Katan MB. Content of Potentially Anticarcinogenic
27
28 Flavonoids of 28 Vegetables and 9 Fruits Commonly Consumed in The
29
30 Netherlands. *J Agric Food Chem* 1992;40:2379-83.
31
32
33 [27] Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo
34
35 biloba brands. *J Pharm Pharmacol* 2002;54:661-9.
36
37
38 [28] Nemeth K, Plumb GW, Berrin JG, Juge N, Jacob R, Naim HY, et al.
39
40 Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical
41
42 step in the absorption and metabolism of dietary flavonoid glycosides in humans.
43
44 *Eur J Nutr* 2003;42:29-42.
45
46
47
48 [29] Nait Chabane M, Al Ahmad A, Peluso J, Muller CD, Ubeaud G. Quercetin and
49
50 naringenin transport across human intestinal Caco-2 cells. *J Pharm Pharmacol*
51
52 2009;61:1473-83.
53
54
55 [30] Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV
56
57 protease inhibitor ritonavir with herbal constituents: changes in P-gp and
58
59 CYP3A4 activity. *Am J Ther* 2004;11:262-77.
60
61
62
63
64
65

- 1
2
3
4 [31] Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR. Effect of
5
6 Ginkgo biloba extract on lopinavir, midazolam and fexofenadine
7
8 pharmacokinetics in healthy subjects. *Curr Med Res Opin* 2008;24:591-9.
9
10
11 [32] Knauer MJ, Urquhart BL, Meyer Zu Schwabedissen HE, Schwarz UI, Lemke CJ,
12
13 Leake BF, et al. Human skeletal muscle drug transporters determine local
14
15 exposure and toxicity of statins. *Circ Res* 2010;106:297-306.
16
17
18 [33] Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum
19
20 concentrations of atorvastatin and has no effect on pravastatin. *Clin Pharmacol*
21
22 *Ther* 1999;66:118-27.
23
24
25 [34] Lee W, Glaeser H, Smith LH, Roberts RL, Moeckel GW, Gervasini G, et al.
26
27 Polymorphisms in human organic anion-transporting polypeptide 1A2
28
29 (OATP1A2): implications for altered drug disposition and central nervous system
30
31 drug entry. *J Biol Chem* 2005;280:9610-7.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

9 Web references

(<http://supplementspot.com>) last date accessed: 20 May 2010

Accepted Manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

10 Figure captions

11 Figure 1: Characterization of the HEK293-OATP1A2 cell line overexpressing OATP1A2.

12 a) Elevated expression of *SLCO1A2* mRNA in HEK293 cells stably expressing
13 OATP1A2 compared with HEK293 cells transfected with the empty vector. b)

14 Immunoblot of OATP1A2 in HEK293-OATP1A2, HEK293-VC, and HEK293 parental
15 cells. At the molecular masses of approximately 60 and 80 kDa, specific signals were
16 detected in HEK293-OATP1A2 cells, which were not detectable in HEK293-VC and
17 HEK293 parental cells. The lower band represents a deglycosylated form of OATP1A2

18 [34] c) Immunofluorescence analysis of HEK293-OATP1A2 cells (left) and HEK293-VC
19 cells (right) using confocal laser scanning microscopy. OATP1A2 was visualized using a
20 Cy3-conjugated antibody (red fluorescence). The localization of OATP1A2 is shown in
21 the x-y, x-z, and y-z layers. OATP1A2 was localized in the plasma membrane and
22 cytosol of the HEK293-OATP1A2 cells, whereas no staining was detectable in the
23 HEK293-VC cells. The nuclei were stained green (original magnification, 400x with 4-
24 fold zoom). d) Uptake of BSP (5 μ M) into HEK293-OATP1A2 and HEK293-VC cells.

25 The HEK293-OATP1A2 cells showed a significantly higher uptake (2.4-fold) of BSP
26 (measured by liquid scintillation counting) compared to HEK293-VC cells (**
27 $p < 0.0001$, unpaired t-test with Welch's correction). e) Uptake of atorvastatin (5 μ M) into HEK293-
28 OATP1A2 and HEK293-VC cells. The HEK293-OATP1A2 cells showed a significantly
29 higher uptake (6.9-fold) of atorvastatin (measured by liquid scintillation counting)
30 compared to HEK293-VC cells (**
31 $p < 0.0001$, unpaired t-test with Welch's correction).

32 All data are presented as means \pm S.E.M.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 Figure 2: Inhibition of OATP1A2- and OATP2B1-mediated BSP transport (measured by
8 liquid scintillation counting) by flavonoids. Dixon plots of inhibition of OATP1A2- (a, b, c)
9 and OATP2B1- (d, e, f) mediated uptake of BSP by apigenin (a, d), kaempferol (b, e)
10 and quercetin (c, f) in HEK293 cells stably expressing OATP1A2 and OATP2B1,
11 respectively. BSP transport (5 min for OATP1A2, 10 min for OATP2B1) at three
12 different concentrations was determined in the absence or presence of increasing
13 concentrations of flavonoids. The reciprocal velocity is plotted against the inhibitor
14 concentration. Data points represent the mean \pm S.E.M. \square , 2.5 μ M BSP; Δ , 5 μ M BSP;
15 \circ , 10 μ M BSP; \blacksquare , 0.5 μ M BSP; \blacktriangle , 1 μ M BSP; \bullet , 5 μ M BSP.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 Figure 3: Inhibition of OATP1A2-mediated fexofenadine transport (measured by LC-
32 MS/MS) by flavonoids. Concentration-dependent effects of apigenin (a), kaempferol (b),
33 and quercetin (c) on OATP1A2-mediated fexofenadine (5 μ M) uptake (5 min). The data
34 are expressed as percentage of control (uptake without flavonoids). All data are
35 presented as means \pm S.E.M.
36
37
38
39
40
41
42
43
44

45 Figure 4: Inhibition of OATP1A2- and OATP2B1-mediated atorvastatin (5 μ M and
46 0.5 μ M, respectively) transport (10 min, measured by liquid scintillation counting) by
47 flavonoids. Concentration-dependent effects of apigenin (a, d), kaempferol (b, e), and
48 quercetin (c, f) on OATP1A2- and OATP2B1-mediated atorvastatin uptake. The data
49 are expressed as percentage of control (uptake without flavonoids). All data are
50 presented as means \pm S.E.M.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




figure 1




figure 1




figure 2

OATP1A2




figure 3




figure 4

Manuscript

